| Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. | |
| | |
MedLine Citation:
|
PMID: 20807330 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
INTRODUCTION: Elderly men may suffer from late-onset hypogonadism (LOH). The long-term effects of long-acting testosterone undecanoate (TU) in a large number of LOH men have not yet been reported. Aims. We analyzed the effects of normalization of plasma testosterone (T) in LOH men. METHODS: The records of 161 men with LOH (baseline T<300 ng/dL) were reviewed and 100 men had used parenteral TU for >12 months. The mean duration of treatment was 90.6 weeks (54 to 150 weeks). MAIN OUTCOME MEASURES: Body mass index (BMI), waist circumference, percentage body fat, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, prostate-specific antigen (PSA), and hematocrit were measured. Further the Aging Male Symptoms' scale (AMS) and the International Index of Erectile Function (IIEF-5 and 15) were scored. RESULTS: T therapy was associated with a significant decline in waist circumference (P=0.028) and percentage body fat (P<0.001), but no change of BMI. Total cholesterol and LDL cholesterol declined significantly (P=0.005 and P=0.024, respectively), with no significant changes of HDL cholesterol and triglycerides. The scores of sub-scales of AMS (psychological, somotovegetative and sexual factors) decreased (P=0.044, P=0.200 and P=0.071, respectively). The mean IIEF-5 (P=0.011) and IIEF-15 scores (P=0.021) improved significantly. Erectile function domain, orgasmic function domain, sexual desire domain, intercourse satisfaction domain, and overall satisfaction domain improved. Median PSA rose from 0.95 (0.640; 1.558) ng/mL to 1.480 (1.015; 2.275) ng/mL (P<0.001), with 11 patients >4 ng/mL (4.01-13.21). On biopsy there was no evidence for malignancy. The mean hematocrit level increased significantly from 42.3±3.4% to 47.1±3.8%. CONCLUSIONS: Normalizing serum T in men with LOH resulted in improvement of the metabolic syndrome, mood and sexual functions and appeared acceptably safe. |
| | |
Authors:
|
Sompol Permpongkosol; Nakorn Tantirangsee; Krisada Ratana-olarn |
Publication Detail:
|
Type: Journal Article Date: 2010-08-30 |
Journal Detail:
|
Title: The journal of sexual medicine Volume: 7 ISSN: 1743-6109 ISO Abbreviation: J Sex Med Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101230693 Medline TA: J Sex Med Country: United States |
Other Details:
|
Languages: eng Pagination: 3765-74 Citation Subset: IM |
Copyright Information:
|
© 2010 International Society for Sexual Medicine. |
Affiliation:
|
Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. sompolpermpongl@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endotheli...
Next Document: The impact of erectile dysfunction on the quality of life of men undergoing hemodialysis and its ass...